Cargando…
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
PURPOSE: Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) assessment in comparison with a tissue-based standard. PATIENTS AND METHODS: The performance of...
Autores principales: | Nakamura, Yoshiaki, Okamoto, Wataru, Denda, Tadamichi, Nishina, Tomohiro, Komatsu, Yoshito, Yuki, Satoshi, Yasui, Hisateru, Esaki, Taito, Sunakawa, Yu, Ueno, Makoto, Shinozaki, Eiji, Matsuhashi, Nobuhisa, Ohta, Takashi, Kato, Ken, Ohtsubo, Koushiro, Bando, Hideaki, Hara, Hiroki, Satoh, Taroh, Yamazaki, Kentaro, Yamamoto, Yoshiyuki, Okano, Naohiro, Terazawa, Tetsuji, Kato, Takeshi, Oki, Eiji, Tsuji, Akihito, Horita, Yosuke, Hamamoto, Yasuo, Kawazoe, Akihito, Nakajima, Hiromichi, Nomura, Shogo, Mitani, Ryuta, Yuasa, Mihoko, Akagi, Kiwamu, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974570/ https://www.ncbi.nlm.nih.gov/pubmed/35188805 http://dx.doi.org/10.1200/PO.21.00383 |
Ejemplares similares
-
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
por: Aoki, Yu, et al.
Publicado: (2023) -
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
por: Nakamura, Yoshiaki, et al.
Publicado: (2023) -
Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
por: Jogo, Tomoko, et al.
Publicado: (2021) -
Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in
RAS
wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study
por: Yuki, Satoshi, et al.
Publicado: (2023) -
A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)